Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Intercept Pharmaceuticals

Intercept Pharmaceuticals

New York
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million

Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.

Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."